NVIDIA-backed AI pharmaceutical company Iambic raised $150 million via a US IPO.

NVIDIA (NVDA.O)-backed clinical-stage anti-cancer drug R&D firm Iambic Therapeutics has completed its US initial public offering (IPO), raising $150 million at the midpoint of its indicative price range. Iambic issued approximately 9.38 million shares at $16 apiece. Earlier filings showed the company had set a preliminary price range of $15 to $17 per share. Based on the IPO price and total shares disclosed in the filings, the company’s market capitalization stands at $758 million. The filings a

@tonmelonfest